CJC-1295

Definition

CJC-1295 is a modified form of growth hormone-releasing hormone (GHRH), designed with a drug affinity complex (DAC) that extends its half-life from minutes to days compared to native GHRH. It acts on GHRH receptors in the pituitary gland to stimulate growth hormone (GH) release. It is commonly combined with GHRP (growth hormone-releasing peptide) compounds — particularly ipamorelin — for a synergistic effect on GH secretion through complementary receptor pathways. CJC-1295 is studied for potential benefits including improved body composition (increased lean mass, reduced fat mass), enhanced recovery, improved sleep quality, and anti-aging effects — all mediated through elevated GH and IGF-1. It is not FDA-approved for these indications and its availability through US compounding pharmacies is subject to regulatory review.

Frequently Asked Question

How is CJC-1295 different from actual growth hormone injections?

CJC-1295 stimulates the pituitary gland to produce and release its own growth hormone — it does not administer exogenous HGH directly. This distinction matters clinically: stimulating the pituitary's natural secretion patterns through a secretagogue produces pulsatile GH release that more closely mirrors normal physiology than direct HGH administration, which produces sustained supraphysiological levels and bypasses the normal regulatory feedback loop. This is generally considered a safer and more physiological approach.

Why is CJC-1295 typically combined with ipamorelin?

CJC-1295 acts on GHRH receptors; ipamorelin acts on ghrelin receptors (GHRP receptors) — two different but complementary pathways for stimulating GH release. Used together, they produce synergistic GH secretion greater than either alone while maintaining more physiological pulsatile release patterns. The combination is among the most studied growth hormone secretagogue protocols in the longevity medicine literature.

Is CJC-1295 legal and available through prescription?

CJC-1295 is not FDA-approved for the indications used in adult longevity and body composition medicine. Its availability through US compounding pharmacies exists under specific regulatory conditions that have been subject to increasing FDA scrutiny. Regulatory status in this area changes, and SPOKEmed monitors FDA guidance actively. Before any CJC-1295 prescription, SPOKEmed confirms current compounding availability, discusses the regulatory context with the patient explicitly, and ensures the patient understands the off-label status and the evidence base — which, while promising in clinical practice, does not include large-scale randomized controlled trials for the specific adult indications being targeted.

Why CJC-1295 Matters

Growth hormone secretion declines significantly with age — a process called somatopause — and this decline accelerates during the same decade as the menopausal transition. The compounding effect of GH decline alongside estrogen and testosterone decline creates a particularly challenging metabolic and body composition environment: reduced muscle synthesis, increased fat storage (particularly visceral), impaired sleep quality, and slower recovery. CJC-1295, used as part of a clinically supervised protocol, is one of the tools being applied in longevity medicine to address this compounded decline — by stimulating the pituitary's own GH production rather than introducing exogenous hormone.

How Spokmed Company Uses It

CJC-1295 may be considered at SPOKEmed for appropriate patients as part of a comprehensive longevity and body composition protocol — following individual evaluation of growth hormone status, clinical goals, and current regulatory availability. It is never prescribed without comprehensive clinical assessment.

Related Services

Related Terms

"CJC-1295" Appears in These Categories

Targeted Peptide Support